GlassScriptPhysician profile
Preethy T Thomas
NPI 1881023158
$1,845.97
in general payments reported to CMS, 2019-2025
9 companies · $84.89 in 2025
The $84.89 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $492 · 2023: $310 · 2024: $712 · 2025: $84.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $400.90 | 2021-2024 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $388.98 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $349.03 | 2021-2023 | |
| Axsome Therapeutics, INC. | $245.38 | 2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $122.19 | 2024 | Cobenfy |
| Sage Therapeutics, LLC | $113.23 | 2024 | |
| Alkermes, INC. | $96.22 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $93.61 | 2024 | Austedo Xr |
| Tactile Systems Technology INC | $36.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preethy Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.